Posts Tagged ‘Screening’

Mesothelioma Information : The Mesothelioma Screening Process

Though there is no good screening process for mesothelioma, the causes are clearly known as asbestos exposure, radiation exposure and exposure to certain viruses. Learn about screening for mesothelioma withinformation from an oncologist in this free video on types of cancer. Expert: Dr. Rolf Freter Bio: Dr. Rolf Freter is a hermatologist and oncologist at South Shore Hospital in Weymouth, MA. Filmmaker: Brian T. Sullivan
Video Rating: 0 / 5

Comprehensive Screening and Clinical Assessment for Asbestos-Related Disease

Comprehensive Screening and Clinical Assessment for Asbestos-Related Disease

Examining Mesothelioma disease by juxtaposing various research studies leads to interesting conclusions.  One interesting study is called, “A histochemical study of the asbestos body coating” by M. Governa, C. Rosanda – Br J Ind Med 1972;29:  Here is an excerpt: “Abstract – A histochemical study of the asbestos body coating. Asbestos bodies after iron extraction were tested by histochemical methods for mucopolysaccharides. The results of the reactions suggest that acid mucopolysaccharides are present in the coating of most bodies. During the formation of the bodies acid mucopolysaccharides might act as a matrix for iron deposition on the coating.”

Another interesting study is called, “Medical examination for asbestos-related disease” by Stephen M. Levin MD, P. Elizabeth Kann MD, MPH, Michael B. Lax MD, MPH
Am. J. Ind. Med. 37:6–22, 2000.  Here is an excerpt: “Abstract – There are millions of workers whose exposure to asbestos dust prior to the implementation of asbestos regulation and improved control measures places them at risk of asbestos-related disease today. In addition, workers are still being exposed to significant amounts of asbestos, when asbestos materials in place are disturbed during renovation, repair, or demolition. Given the continued presence of asbestos-containing materials in industrial, commercial, and residential settings throughout the U.S., a sizeable population remains at risk of asbestos-related disease.

This article reviews the health effects associated with exposure to asbestos and delineates the steps necessary for the comprehensive screening and clinical assessment for asbestos-related disease, in order to assist physicians in identifying and preventing illness associated with exposure to asbestos among their patients.”

Another study is called, “Manganese superoxide dismutase genotypes and asbestos-associated pulmonary disorders” by Ari Hirvonena, Jarno Tuimalaa, Tiina Ollikainena, Kaija Linnainmaaa, Vuokko Kinnulab – Volume 178, Issue 1, Pages 71-74 (8 April 2002).  Here is an excerpt: “Abstract – Manganese superoxide dismutase (MnSOD) activity is highly elevated in the biopsies of human asbestos-associated malignant mesothelioma. We therefore examined if polymorphism in the mitochondrial targeting sequence of the MnSOD gene modified individual susceptibility to this malignancy or related asbestos-associated pulmonary disorders. The study population consisted of 124 male Finnish asbestos insulators who were all classified as having been exposed to high levels of asbestos; 63 of the workers had no pulmonary disorders and 61 either had malignant mesothelioma or the non-malignant pulmonary disorders asbestosis and/or pleural plaques. No significant associations were found between the MnSOD genotypes and these ill-health. This study therefore suggest no major modifying role for the MnSOD polymorphism in development of asbestos-associated pulmonary disorders.”

Another interesting study is called, “Cigarette Smoking, Asbestos Exposure, and Malignant Mesothelioma” by Joshua E. Muscat, and Ernst L. Wynder – Cancer Res May 1, 1991 51; 2263.  Here is an excerpt: “Abstract – In a hospital-based case-control study of 124 (105 male and 19 female) histologically confirmed malignant mesothelioma cases and age- and sex-matched controls, the role of cigarette smoking and the risk of asbestos exposure was investigated. Exposure to asbestos for at least 1 year was likely for 78% of male cases and 16% of female cases, and 90% of males were possibly exposed. Male cases worked predominately in the ship-building industry, construction, or insulation trades. Elevated risks were found for males employed in asbestos-related industries [odds ratio (OR) 8.1; 95% confidence interval (CI) 4.9–13.5], e.g., shipyards (OR 82.9, 95% CI 25.5–269.1), construction/maintenance (OR 8.3, 95% CI 4.6–14.8), and other asbestos-related jobs (OR 3.2, 95% CI 1.4–7.2), and for males who self-reported exposure to asbestos or insulation (OR 50.9, 95% CI 21.7–119.8). A statistically significant trend was found for the risk of mesothelioma with increasing years employed in non-shipyard asbestos-related occupations. Among women, only one case worked in an asbestos-related industry and two reported domestic contact with asbestos. No association between cigarette smoking and mesothelioma was found for either men or women. We also report the occurrence of mesothelioma in occupations which have not been previously reported.”

We all owe a debt of gratitude to these fine researchers for their important work.  If you found any of these excerpts helpful, please read the studies in their entirety.

Monty Wrobleski is the author of this article, for more information please click on the following links

Depuy Hip Recall Attorneys

Depuy Hip Recall Lawyers

Mesothelioma Lawyer

Article from

Related Mesothelioma Disease Articles

Screening for Mesothelioma and Serum Osteopontin Level Testing 

Screening for Mesothelioma and Serum Osteopontin Level Testing 

Diagnosis of malignant mesothelioma is often made too late to successfully remove the cancer or halt its progression. Consequently, researchers have been looking for a biomarker that would be definitive in diagnosing metastatic mesothelioma, but, as yet, have not been entirely successful. Serum osteopontin is a molecule whose presence is associated with metastatic mesothelioma. It one of three biomarkers that have raised a lot of interest, and generated many research studies around the world.

One study published in 2007 by the Pulmonary and Thoracic Oncology Department, Hopital Calmette (this is not a misspelling,) Lille, France concludes that osteopontin is not sufficiently specific to diagnose mesothelioma. They did conclude, however, that it might be useful in monitoring the disease. The paper states that cytohistology is still the most accurate diagnostic measure for mesothelioma.

A study published by the Department of Surgery, Wayne State University, Karmanos Cancer Institute, John A. Dingell Veterans Hospital, Detroit, MI noted that the serum osteopontin levels measured notably higher in pleural mesothelioma patients, as compared to a group whose participants had been exposed to asbestos and had various asbestos-related diseases (plaques, fibrosis or both, but not mesothelioma.) Their conclusion was that serum osteopontin levels are useful for distinguishing between patients who have pleural mesothelioma and those that have other asbestos related diseases that are not cancerous.

A study by doctors at Institut National de la Sante et de la Recherche Medicale (INSERM) U774, Institut Pasteur de Lille, Lille, France studied both the diagnostic and prognostic value of osteopontin with slightly different results than other studies revealed. They concluded that osteopontin is less accurate as a diagnostic measure, but may have potential as a prognostic marker.

In a fourth study by doctors at the National Research Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, Nedlands, Australia similar results show that osteopontin is not the marker scientists hope to find. This report added that osteopontin levels did not differentiate between mesothelioma and other malignancies.

Most other studies seem to confirm these results, and each points to two other biomarkers as having the potential to provide differential diagnosis reliability. Of the three, soluble mesothelin-related peptide (SMRP) shows the most promise for both early detection of malignant mesothelioma and differentiating between benign and metastatic carcinomas.

Treatment for mesothelioma can be expensive, and impose great demands on you and your family. If you have been diagnosed with an asbestos-related disease, you may be entitled to a settlement to pay these expenses. Please contact the lawyers experienced in mesothelioma claims in Baltimore, Maryland and Washington, D.C.

Article from